The Journal of
PHARMACOLOGY
And Experimental Therapeutics
A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2017 Vol. 363, No. 1

Contents

MINIREVIEWS

Enhancing Studies of Pharmacodynamic Mechanisms via Measurements of Metabolic Flux: Fundamental Concepts and Guiding Principles for Using Stable Isotope Tracers

BEHAVIORAL PHARMACOLOGY

Assessing the Value of the Zebrafish Conditioned Place Preference Model for Predicting Human Abuse Potential
A. J. Brock, S. M. G. Goody, A. N. Mead, A. Sudwarts, M.O. Parker, and C.H. Brennan

CARDIOVASCULAR

Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis
Yasmine F. Ibrahim, Nataliia V. Shults, Vladyslava Rybka, and Yuichiro J. Suzuki

CELLULAR AND MOLECULAR

CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome
Raymond H. de Wit, Raimond Heukers, Hendrik J. Brink, Angela Arsova, David Maussang, Pasquale Cutolo, Beatrijs Strubbe, Henry F. Vischer, Françoise Bachelerie, and Martine J. Smit

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
De Lin, Rumen Kostov, Jeffrey T.-J. Huang, Colin J. Henderson, and C. Roland Wolf

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration
Maciej Salaga, Anna Mokrowiec, Marta Zielinska, Ewa Malecka-Panas, Radzislaw Kordek, Elzbieta Kamysz, and Jakub Fichna

Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress
John G. Yonchuk, Joseph P. Foley, Brian J. Bolognese, Gregory Logan, William E. Wixted, Jen-Pyng Kou, Diana G. Chalupowicz, Heidi G. Feldser, Yolanda Sanchez, Hong Nie, James F. Callahan, Jeffrey K. Kerns, and Patricia L. Podolin

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Mechanistic Multi—Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics
Vivaswath S. Ayyar, Debra C. DuBois, Richard R. Almon, and William J. Jusko

NEUROPHARMACOLOGY

Ethanol Exposure Regulates Gabral Expression via Histone Deacetylation at the Promoter in Cultured Cortical Neurons
John Peyton Bohnsack, Vraj K. Patel, and A. Leslie Morrow
Urolithin A Mitigates Cisplatin-Induced Nephrotoxicity by Inhibiting Renal Inflammation and Apoptosis in an Experimental Rat Model

Melissa Guada, Raghu Ganugula, Manicka Vadhanam, and Majeti N.V. Ravi Kumar

NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential


Supplemental material is available at jpet.aspetjournals.org.

About the cover: Urolithin A mitigates cisplatin-induced nephrotoxicity in rats by modulation of the inflammatory cascade and inhibition of the pro-apoptotic pathway. See the article by Guada et al., (dx.doi.org/10.1124/jpet.117.242420).